Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Amino-PEG4-(S,R,S)-AHPC-Me is a ligand-linker conjugate designed for E3 ligase targeting. This compound facilitates the development of PROTACs, specifically enabling the synthesis of NR-V04. It is utilized in research applications focused on targeted protein degradation and the modulation of protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
(S)-Thalidomide-azetidine-O-Pip is an E3 ligase ligand-linker conjugate designed for targeted protein degradation via the knockdown of specific proteins. This compound features a CRBN-based ligand that enables the selective recruitment of E3 ligases, facilitating the formation of PROTACs (PROteolysis TArgeting Chimeras). It is valuable in studies focused on therapeutic strategies, cancer research, and functional proteomics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C10-Boc is a conjugate designed as an E3 ubiquitinase ligand-linker, facilitating the recruitment of the Cereblon ubiquitinase. This compound enables the synthesis of PROTAC molecules that induce targeted protein degradation, through its versatile PTOTAC linker. It has applications in developing therapeutics by coupling with specific ligands, such as EP300/CBP ligand 2, to create PROTACs that promote proteolytic activity against designated targets. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-COCH-PEG2-azido is an E3 ligase ligand-linker conjugate designed to target cereblon, facilitating the development of targeted protein degradation strategies. This compound plays a crucial role in synthesizing PROTAC AKR1C3 degrader-1, aiding researchers in studying protein turnover and degradation pathways. It is particularly useful in the investigation of cellular responses to E3 ligase modulation and the development of novel biotherapeutic approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-Triazole-C4-amino is an E3 ligase ligand-linker conjugate that facilitates the formation of proteolysis-targeting chimeras (PROTACs). This compound is essential for researchers investigating targeted protein degradation mechanisms, providing a robust approach to modulate specific protein levels within cells. It plays a significant role in drug development and environmental toxicity research applications by enabling the selective degradation of disease-related proteins. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 109 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC SOS1 degrader. This compound facilitates targeted protein degradation, enabling researchers to investigate the therapeutic potential of protein modulation in cellular systems. Its utility in developing targeted degradation strategies makes it an essential tool for drug discovery and development research. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-pent-4-yn-1-ol is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of PROTACs (proteolysis-targeting chimeras). This compound utilizes a CRBN-based ligand in conjunction with a pent-4-yn-1-ol linker, enabling targeted degradation of proteins through the ubiquitin-proteasome pathway. It serves as a valuable tool for studying protein regulation and therapeutic interventions in diseases related to protein misfolding and degradation. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-Me-8-bromooctanoic acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC compounds. This reagent facilitates the targeted degradation of proteins, specifically functioning in the development of CYP1B1 degrader-2. It is a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications in drug discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-((3R)-3-pyrrolidinemethanol) is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and attached linker. This compound is essential for the design and synthesis of PROTACs (proteolysis targeting chimeras), which facilitate the degradation of specific proteins within cellular systems. Its ability to selectively target E3 ligases makes it a valuable tool in chemical biology research and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 108 is an E3 ligase ligand-linker conjugate designed for the synthesis of targeted protein degradation compounds. This reagent facilitates the development of PROTACs, specifically enabling the degradation of the SOS1 protein. It serves as a crucial tool in research applications focused on targeted protein modulation and therapeutic intervention in cellular processes related to disease states. -
E3 Ligase Ligand-Linker Conjugate
tert-Butyl (S)-5-amino-4-(4-hydroxy-1-oxoisoindolin-2-yl)-5-oxopentanoate serves as an E3 ligase ligand-linker conjugate specifically designed for the development of PROTACs (proteolysis-targeting chimeras). This compound features a CRBN-based ligand essential for targeted protein degradation mechanisms. Its application in research facilitates the selective modulation of protein levels, contributing to studies in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide 5'-piperazine-C1-piperidine is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand coupled with a linker moiety. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation. Its primary application lies in the study and modulation of protein levels in various biological contexts, making it an essential tool for cancer research and drug discovery. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C3-COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand combined with a linker structure derived from (S,R,S)-AHPC. This versatile compound facilitates the design and synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation. Its unique structure supports research applications in targeted therapy and cellular protein regulation studies. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 214 is an innovative E3 ligase ligand-linker conjugate featuring a Von Hippel-Lindau (VHL) ligand. This compound effectively binds to target proteins, facilitating the formation of PROTAC (Proteolysis Targeting Chimeras) molecules, such as the PROTAC LSD1 Degrader 1. Its application in targeted protein degradation research supports the development of novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-COOH is an E3 ligase ligand-linker conjugate designed for the construction of PROTACs. It incorporates the VH032 VHL-based ligand, which is a selective and potent inhibitor of the VHL/HIF-1α interaction with a Kd of 185 nM. This compound is valuable for investigating models of anemia and ischemic diseases, providing a tool for targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugates
DCAF11 ligand-Linker Conjugate 1 is a conjugate designed to facilitate targeted protein degradation through the DCAF11 E3 ubiquitin ligase. This compound serves as a key component for synthesizing PROTAC LGF308, enabling the selective degradation of specific proteins within cellular systems. Its utility in research applications includes the exploration of protein degradation pathways and investigating therapeutic targets in cancer and other diseases.
